ARCUS BIOSCIENCES INC (RCUS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RCUS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RCUS | Director | 56 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| GILD | Chief Commercial and Corporate Affairs Officer | 56 | ["Central to Gilead\u2019s portfolio diversification", "Orchestrated the historic launch of a novel, long-acting option for HIV prevention", "Led the rapid launch and global access efforts for Gilead\u2019s COVID-19 antiviral", "Champion of responsible, ethical use of artificial intelligence", "Passionate advocate for transformational healthcare", "Led successful U.S. launch of Yeztugo for HIV prevention", "Achieved >85% U.S. payer access ahead of schedule", "Secured partnerships with the Global Fund and U.S. State Department", "Oversaw Phase 3 clinical trials of Trodelvy"] | ["Arcus Biosciences", "Neurocrine Biosciences", "University of Southern California\u2019s Leonard D. Schaeffer Center for Health Policy and Economics"] | 2026 |
| NBIX | ["Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Human Capital Management"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 |
Biography sourced from the proxy statement filing.
Johanna Mercier has served as a member of the Board since January 2024. Ms. Mercier has served as the Chief Commercial Officer of Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company, since May 2019. In her role at Gilead, she is responsible for overseeing the global commercialization of all of Gilead s medicines throughout the product lifecycle. Prior to Gilead, she served in a number of executive leadership positions over 25 years at Bristol-Myers Squibb including as President, U.S. & Large Markets from September 2018 until May 2019, President, U.S. from August 2017 until October 2018 and President, European Markets, Australia & Canada from August 2016 until August 2017. In her roles at Bristol-Myers Squibb, she gained broad experience across geographies and in all aspects of the commercial business and she led the execution of multiple launches that changed the standard of care in melanoma and renal cancers. Ms. Mercier holds a bachelor s degree in biology from the University of Montreal and an MBA from Concordia University. She currently serves on the board of directors of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and the University of Southern California s Leonard D. Schaeffer Center for Health Policy and Economics. Ms. Mercier was selected to be appointed to the Board pursuant to the Investor Rights Agreement and we believe she is able to make valuable contributions to the Board due to her extensive commercial experience and her current role at Gilead Sciences, Inc.